PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

被引：0
|
作者：
Bagley, Stephen J. [1 ,2 ]
Bauml, Joshua M. [1 ,2 ]
Langer, Corey J. [1 ,2 ]
机构：
[1] Abramson Canc Ctr, Div Hematol Oncol, Philadelphia, PA 19104 USA
[2] Hosp Univ Penn, Philadelphia, PA 19104 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2015年 / 13卷 / 10期
关键词：
Checkpoint inhibitors; immunotherapy; nivolumab; non-small cell lung cancer (NSCLC); PD-1; pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The programmed death 1 (PD-1) pathway is an immune checkpoint that has been implicated in tumoral immune escape, and has emerged as a major focus of immunotherapy in nonsmall cell lung cancer (NSCLC). Multiple agents have progressed through clinical development in recent years, including antibodies targeting both PD-1 and its key ligand, programmed death ligand 1 (PD-L1). This article reviews PD-1/PD-L1 blockade in NSCLC, including completed clinical trials, ongoing studies, future directions, and challenges.
引用
收藏
页码：676 / 683
页数：8
相关论文
共 50 条
  • [1] Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
    Luo, Fan
    Luo, Min
    Rong, Qi-Xiang
    Zhang, Hong
    Chen, Zhen
    Wang, Fang
    Zhao, Hong-Yun
    Fu, Li-Wu
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
  • [2] SRC inhibitor saracatinib enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
    Lu, Fei-Teng
    Luo, Fan
    Qiu, Miao-Zhen
    Cao, Jia-Xin
    Luo, Qiu-Yun
    Yang, Da-Jun
    Zhao, Hong-Yun
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [3] Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer
    Shien, Kazuhiko
    Papadimitrakopoulou, Vassiliki A.
    Wistuba, Ignacio I.
    [J]. LUNG CANCER, 2016, 99 : 79 - 87
  • [4] PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges
    Meng, Xiangjiao
    Liu, Yanli
    Zhang, Jianjun
    Teng, Feifei
    Xing, Ligang
    Yu, Jinming
    [J]. CANCER LETTERS, 2017, 405 : 29 - 37
  • [5] Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
    Huang, Mu-Yang
    Jiang, Xiao-Ming
    Wang, Bing-Lin
    Sun, Yang
    Lu, Jin-Jian
    [J]. PHARMACOLOGY & THERAPEUTICS, 2021, 219
  • [6] PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer
    Shankar, Bairavi
    Naidoo, Jarushka
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S4034 - S4037
  • [7] Research progression of PD-1/PD-L1 in non-small cell lung cancer
    Xing Liu
    Xiaodong Xie
    [J]. Oncology and Translational Medicine, 2017, 3 (03) : 111 - 115
  • [8] Targeting the PD-1/PD-L1 axis in non-small cell lung cancer
    Kumar, Rajiv
    Collins, Dearbhaile
    Dolly, Saoirse
    McDonald, Fiona
    O'Brien, Mary E. R.
    Yap, Timothy A.
    [J]. CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 111 - 124
  • [9] PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
    Hartkopf, Andreas D.
    Taran, Florin-Andrei
    Wallwiener, Markus
    Walter, Christina B.
    Kraemer, Bernhard
    Grischke, Eva-Maria
    Brucker, Sara Y.
    [J]. BREAST CARE, 2016, 11 (06) : 385 - 390
  • [10] Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
    Eltahir, Mohamed
    Isaksson, Johan
    Mattsson, Johanna Sofia Margareta
    Karre, Klas
    Botling, Johan
    Lord, Martin
    Mangsbo, Sara M.
    Micke, Patrick
    [J]. CANCERS, 2021, 13 (13)
12345